Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Pancreatic Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Salivary Gland Neoplasms 1Rhabdomyosarcoma, Alveolar 1Penile Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Mouth Neoplasms 1Mesothelioma, Malignant 1Lymphoma 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Neuroendocrine 1Carcinoma 1

Interventions

Vinorelbine 2Vincristine 2Radiotherapy 2Radiation 2Dactinomycin 2Cyclophosphamide 2temsirolimus 1X-Rays 1Specimen Handling 1Sirolimus 1Phantoms, Imaging 1Magnetic Resonance Spectroscopy 1Irinotecan 1Biopsy 1BAY 1895344 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Rhabdomyosarcoma, Alveolar × BAY 1895344 × Clear all
NCT05071209 2026-01-23

Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
31 enrolled 14 charts
LymphoidSarcoma

Lymphoma, Sarcoma, Ewing, Rhabdomyosarcoma, Alveolar

Data powered by HemOnc (CC BY 4.0) Colophon âš¡